Intervacc AB (publ) announced that the first batch of Strangvac, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the vaccine in Italy and in a number of other European countries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.04 SEK | -0.49% | -3.46% | -36.18% |
Mar. 04 | Intervacc AB Announces Changes in the Nomination Committee | CI |
Feb. 28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.18% | 28.24M | |
-3.04% | 104B | |
+0.89% | 97.42B | |
+0.79% | 22.2B | |
-17.69% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-16.42% | 15.06B | |
+3.94% | 13.98B | |
+32.86% | 11.66B |
- Stock Market
- Equities
- IVACC Stock
- News Intervacc AB
- Intervacc AB Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy